Terumo BCT Unveils Automated CAR-T Manufacturing Platform Delivering 12 Billion Cells in 7-8 Days
Terumo BCT has developed a new automated workflow that consolidates T cell activation, viral transduction, and expansion into a single platform, streamlining CAR-T manufacturing significantly.
Gamma Delta T Cells Emerge as Promising Alternative to CAR-T for Solid Tumors and Autoimmune Diseases
• Gamma delta T cells demonstrate unique potential in treating solid tumors and autoimmune conditions, operating independently of HLA matching and showing minimal toxicity toward healthy cells. • Despite representing only 1-5% of total T cells in peripheral blood, gamma delta T cells are gaining attention with a 50% increase in companies pursuing their development over the past year. • Manufacturing challenges persist due to limited cell availability, but experts remain optimistic about scaling potential and advantages over traditional CAR-T therapies, particularly in reducing side effects like cytokine release syndrome.